Coagulation of human prostate volumes with MRI-controlled transurethral ultrasound therapy: Results in gel phantoms

William Apoutou N'Djin, Mathieu Burtnyk, Ilya Kobelevskiy, Stefan Hadjis, Michael Bronskill, Rajiv Chopra

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

Purpose: The feasibility and safety of magnetic resonance imaging (MRI)-controlled transurethral ultrasound therapy were demonstrated recently in a preliminary human study in which a small subvolume of prostate tissue was treated prior to radical prostatectomy. Translation of this technology to full clinical use, however, requires the capability to generate thermal coagulation in a volume up to that of the prostate gland itself. The aim of this study was to investigate the parameters required to treat a full 3D human prostate accurately with a multi-element transurethral applicator and multiplanar MR temperature control. Methods: The approach was a combination of simulations (to select appropriate parameters) followed by experimental confirmation in tissue-mimicking phantoms. A ten-channel, MRI-compatible transurethral ultrasound therapy system was evaluated using six human prostate models (average volume: 36 cm3) obtained from the preliminary human feasibility study. Real-time multiplanar MR thermometry at 3 T was used to control the spatial heating pattern in up to nine planes simultaneously. Treatment strategies incorporated both single (4.6 or 8.1 MHz) and dual (4.6 and 14.4 MHz) frequencies, as well as maximum acoustic surface powers of 10 or 20 W cm -2. Results: Treatments at 4.6 MHz were capable of coagulating a volume equivalent to 97 of the prostate. Increasing power from 10 to 20 W cm-2 reduced treatment times by approximately 50 with full treatments taking 26 ± 3 min at a coagulation rate of 1.8 ± 0.4 cm 3 min-1. A dual-frequency 4.614.4 MHz treatment strategy was shown to be the most effective configuration for achieving full human prostate treatment while maintaining good treatment accuracy for small treatment radii. The dual-frequency approach reduced overtreatment close to the prostate base and apex, confirming the simulations. Conclusions: This study reinforces the capability of MRI-controlled transurethral ultrasound therapy to treat full prostate volumes in a short treatment time with good spatial targeting accuracy and provides key parameters necessary for the next clinical trial.

Original languageEnglish (US)
Pages (from-to)4524-4536
Number of pages13
JournalMedical Physics
Volume39
Issue number7
DOIs
StatePublished - Jul 2012

Fingerprint

Prostate
Gels
Magnetic Resonance Imaging
Therapeutics
Thermometry
Feasibility Studies
Prostatectomy
Acoustics
Heating
Hot Temperature
Clinical Trials
Technology
Safety
Temperature

Keywords

  • cancer
  • human prostate
  • MRT feedback
  • thermal therapy
  • transurethral ultrasound

ASJC Scopus subject areas

  • Biophysics
  • Radiology Nuclear Medicine and imaging

Cite this

Coagulation of human prostate volumes with MRI-controlled transurethral ultrasound therapy : Results in gel phantoms. / N'Djin, William Apoutou; Burtnyk, Mathieu; Kobelevskiy, Ilya; Hadjis, Stefan; Bronskill, Michael; Chopra, Rajiv.

In: Medical Physics, Vol. 39, No. 7, 07.2012, p. 4524-4536.

Research output: Contribution to journalArticle

N'Djin, William Apoutou ; Burtnyk, Mathieu ; Kobelevskiy, Ilya ; Hadjis, Stefan ; Bronskill, Michael ; Chopra, Rajiv. / Coagulation of human prostate volumes with MRI-controlled transurethral ultrasound therapy : Results in gel phantoms. In: Medical Physics. 2012 ; Vol. 39, No. 7. pp. 4524-4536.
@article{9349836ad988416db785ef3d24548d27,
title = "Coagulation of human prostate volumes with MRI-controlled transurethral ultrasound therapy: Results in gel phantoms",
abstract = "Purpose: The feasibility and safety of magnetic resonance imaging (MRI)-controlled transurethral ultrasound therapy were demonstrated recently in a preliminary human study in which a small subvolume of prostate tissue was treated prior to radical prostatectomy. Translation of this technology to full clinical use, however, requires the capability to generate thermal coagulation in a volume up to that of the prostate gland itself. The aim of this study was to investigate the parameters required to treat a full 3D human prostate accurately with a multi-element transurethral applicator and multiplanar MR temperature control. Methods: The approach was a combination of simulations (to select appropriate parameters) followed by experimental confirmation in tissue-mimicking phantoms. A ten-channel, MRI-compatible transurethral ultrasound therapy system was evaluated using six human prostate models (average volume: 36 cm3) obtained from the preliminary human feasibility study. Real-time multiplanar MR thermometry at 3 T was used to control the spatial heating pattern in up to nine planes simultaneously. Treatment strategies incorporated both single (4.6 or 8.1 MHz) and dual (4.6 and 14.4 MHz) frequencies, as well as maximum acoustic surface powers of 10 or 20 W cm -2. Results: Treatments at 4.6 MHz were capable of coagulating a volume equivalent to 97 of the prostate. Increasing power from 10 to 20 W cm-2 reduced treatment times by approximately 50 with full treatments taking 26 ± 3 min at a coagulation rate of 1.8 ± 0.4 cm 3 min-1. A dual-frequency 4.614.4 MHz treatment strategy was shown to be the most effective configuration for achieving full human prostate treatment while maintaining good treatment accuracy for small treatment radii. The dual-frequency approach reduced overtreatment close to the prostate base and apex, confirming the simulations. Conclusions: This study reinforces the capability of MRI-controlled transurethral ultrasound therapy to treat full prostate volumes in a short treatment time with good spatial targeting accuracy and provides key parameters necessary for the next clinical trial.",
keywords = "cancer, human prostate, MRT feedback, thermal therapy, transurethral ultrasound",
author = "N'Djin, {William Apoutou} and Mathieu Burtnyk and Ilya Kobelevskiy and Stefan Hadjis and Michael Bronskill and Rajiv Chopra",
year = "2012",
month = "7",
doi = "10.1118/1.4730288",
language = "English (US)",
volume = "39",
pages = "4524--4536",
journal = "Medical Physics",
issn = "0094-2405",
publisher = "AAPM - American Association of Physicists in Medicine",
number = "7",

}

TY - JOUR

T1 - Coagulation of human prostate volumes with MRI-controlled transurethral ultrasound therapy

T2 - Results in gel phantoms

AU - N'Djin, William Apoutou

AU - Burtnyk, Mathieu

AU - Kobelevskiy, Ilya

AU - Hadjis, Stefan

AU - Bronskill, Michael

AU - Chopra, Rajiv

PY - 2012/7

Y1 - 2012/7

N2 - Purpose: The feasibility and safety of magnetic resonance imaging (MRI)-controlled transurethral ultrasound therapy were demonstrated recently in a preliminary human study in which a small subvolume of prostate tissue was treated prior to radical prostatectomy. Translation of this technology to full clinical use, however, requires the capability to generate thermal coagulation in a volume up to that of the prostate gland itself. The aim of this study was to investigate the parameters required to treat a full 3D human prostate accurately with a multi-element transurethral applicator and multiplanar MR temperature control. Methods: The approach was a combination of simulations (to select appropriate parameters) followed by experimental confirmation in tissue-mimicking phantoms. A ten-channel, MRI-compatible transurethral ultrasound therapy system was evaluated using six human prostate models (average volume: 36 cm3) obtained from the preliminary human feasibility study. Real-time multiplanar MR thermometry at 3 T was used to control the spatial heating pattern in up to nine planes simultaneously. Treatment strategies incorporated both single (4.6 or 8.1 MHz) and dual (4.6 and 14.4 MHz) frequencies, as well as maximum acoustic surface powers of 10 or 20 W cm -2. Results: Treatments at 4.6 MHz were capable of coagulating a volume equivalent to 97 of the prostate. Increasing power from 10 to 20 W cm-2 reduced treatment times by approximately 50 with full treatments taking 26 ± 3 min at a coagulation rate of 1.8 ± 0.4 cm 3 min-1. A dual-frequency 4.614.4 MHz treatment strategy was shown to be the most effective configuration for achieving full human prostate treatment while maintaining good treatment accuracy for small treatment radii. The dual-frequency approach reduced overtreatment close to the prostate base and apex, confirming the simulations. Conclusions: This study reinforces the capability of MRI-controlled transurethral ultrasound therapy to treat full prostate volumes in a short treatment time with good spatial targeting accuracy and provides key parameters necessary for the next clinical trial.

AB - Purpose: The feasibility and safety of magnetic resonance imaging (MRI)-controlled transurethral ultrasound therapy were demonstrated recently in a preliminary human study in which a small subvolume of prostate tissue was treated prior to radical prostatectomy. Translation of this technology to full clinical use, however, requires the capability to generate thermal coagulation in a volume up to that of the prostate gland itself. The aim of this study was to investigate the parameters required to treat a full 3D human prostate accurately with a multi-element transurethral applicator and multiplanar MR temperature control. Methods: The approach was a combination of simulations (to select appropriate parameters) followed by experimental confirmation in tissue-mimicking phantoms. A ten-channel, MRI-compatible transurethral ultrasound therapy system was evaluated using six human prostate models (average volume: 36 cm3) obtained from the preliminary human feasibility study. Real-time multiplanar MR thermometry at 3 T was used to control the spatial heating pattern in up to nine planes simultaneously. Treatment strategies incorporated both single (4.6 or 8.1 MHz) and dual (4.6 and 14.4 MHz) frequencies, as well as maximum acoustic surface powers of 10 or 20 W cm -2. Results: Treatments at 4.6 MHz were capable of coagulating a volume equivalent to 97 of the prostate. Increasing power from 10 to 20 W cm-2 reduced treatment times by approximately 50 with full treatments taking 26 ± 3 min at a coagulation rate of 1.8 ± 0.4 cm 3 min-1. A dual-frequency 4.614.4 MHz treatment strategy was shown to be the most effective configuration for achieving full human prostate treatment while maintaining good treatment accuracy for small treatment radii. The dual-frequency approach reduced overtreatment close to the prostate base and apex, confirming the simulations. Conclusions: This study reinforces the capability of MRI-controlled transurethral ultrasound therapy to treat full prostate volumes in a short treatment time with good spatial targeting accuracy and provides key parameters necessary for the next clinical trial.

KW - cancer

KW - human prostate

KW - MRT feedback

KW - thermal therapy

KW - transurethral ultrasound

UR - http://www.scopus.com/inward/record.url?scp=84864184796&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84864184796&partnerID=8YFLogxK

U2 - 10.1118/1.4730288

DO - 10.1118/1.4730288

M3 - Article

C2 - 22830784

AN - SCOPUS:84864184796

VL - 39

SP - 4524

EP - 4536

JO - Medical Physics

JF - Medical Physics

SN - 0094-2405

IS - 7

ER -